Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5320-5328

  Ma, Wenbin ^a   Tessarollo, Lino ^a   Hong, Seung Beom ^a   Baba, Masaya ^b   Southon, Eileen ^a   Back, Timothy C ^a   Spence, Sally ^a   Lobe, Corrinne G ^c   Sharma, Nirmala ^a   Maher, Gregory W ^a   Pack, Svetlana ^d   Vortmeyer, Alexander O ^d   Guo, Chuanfa ^e   Zbar, Berton ^a   Schmidt, Laura S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d National Institute of Neurological Disorders   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELISM; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; GENE; GENE CRE; GENE INACTIVATION; GENETIC RECOMBINATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; IN VIVO STUDY; INFERTILITY; KNOCKOUT MOUSE; LIVER TUMOR; LIVER VASCULAR TUMOR; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SPERMATOGENESIS; SPERMATOZOON COUNT; SURVIVAL; TRANSGENE; VASCULAR TUMOR; VHL GENE; VON HIPPEL LINDAU DISEASE;

ACTINS; ALLELES; ANIMALS; DISEASE MODELS, ANIMAL; DNA NUCLEOTIDYLTRANSFERASES; DNA-BINDING PROTEINS; FEMALE; GENE SILENCING; HEMANGIOMA; HIPPEL-LINDAU DISEASE; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); RECOMBINASES; RECOMBINATION, GENETIC; SPERMATOGENESIS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 0141816848     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Glenn, G., Choyke, P., Zbar, B., and Linehan, W. M. von Hippel-Lindau disease: clinical review and molecular genetics. Probl. Urol., 4: 312-330, 1990.
2. Couch, V., Lindor, N. M., Karnes, P. S., and Michels, V. V. Von Hippel-Lindau disease. Mayo Clin. Proc., 75: 265-272, 2000.
3. Simms, K. B. Von Hippel-Lindau disease: gene to bedside. Curr. Opin. Neurol., 14: 695-703, 2001.
4. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F. M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., Schmidt. L., Zhou, F., Li, H., Wei, M. H., Chen, F., Glenn, G., Choyke, P., Walther, M. M., Weng, Y., Duan, D-S. R., Dean, M., Glavac, D., Richards, F. M., Crossey, P. A., Ferguson-Smith, M. A., Pasiler, D. L., Chumakov, I., Cohen, D., Chinault, S. C., Maher, E. R., Linehan, W. M., Zbar, B., and Lerman, M. L. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (Wash. DC), 260: 1317-1320, 1993.
5. Chen, F., Kishida, T., Yao, M., Hustad, T., Glavac, D., Dean, M., Gnarra, J., Orcutt, M. L., Duh, F. M., Glenn, G., Green, J., Hsia, Y. E., Lamiell, J., Li, H., Wei, M. W., Schmidt, L., Tory, K., Kuzmin, I., Stackhouse, T., Latif, F., Linehan, W. M., Lerman, M., and Zbar, B. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat., 5: 66-75, 1995.
6. Glavac, D., Neumann, H. P., Wittke, C., Jaenig, H., Masek, O., Streicher, T., Pausch, F., Engelhardt, D., Plate, K. H., Hofler, H., Chen, F., Zbar, B., and Brauch, H. Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum. Genet., 98: 271-280, 1996.
7. Zbar, B., Kishida, T., Chen, F., Schmidt, L., Maher, E. R., Richards, F. M., Crossey, P. A., Webster, A. R., Affara, N. A., Ferguson-Smith, M. A., Brauch, H., Glavac, D., Neumann, H. P. H., Tisherman, S., Mulvihill, J. J., Gross, D. J., Shuin, T., Whaley, J., Seizinger, B., Kley, N., Olschwang, S., Boisson, C., Richard, S., Lips, C. H., Lerman. M., et al. Germline mutations in the von Hippel-Lindau (VHL) gene families from North America, Europe and Japan. Hum. Mutat., 8: 348-357, 1996.
8. Gnarra, J. R., Tory, Y., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F-M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B., and Linehan, W. M. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat. Genet., 7: 85-90, 1994.
9. Kanno, H., Kondo, K., Ito, S., Yamamoto, I., Fujii, S., Torigoes, S., Sakai, N., Hosaka, M., Shuin, T., and Yao, M. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res., 54: 4845-4847, 1994.
10. Oberstrass, J., Reifenberger, G., Reifenberger, J., Wechsler, W., and Collins, V. P. Mutation of the von Hippel-Lindau tumor suppressor gene in capillary haemangioblastomas of the central nervous system. J. Pathol., 179: 151-156, 1996.
11. Gilcrease, M. Z., Schmidt, L., Zbar, B., Truong, L., Rutledge, M., and Wheeler, T. M. Somatic von Hippel-Lindau mutation in clear cell papillary cystadenomas of the epididymis. Hum. Pathol., 26: 1341-1346, 1995.
12. Linchan, W. M., Lerman, M. I., and Zbar, B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. J. Am. Med. Assoc., 27: 564-570, 1995.
13. Friedrich, C. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum. Mol. Genet., 10: 763-767, 2001.
14. Stolle, C., Glenn, G., Zbar, B., Humphrey, J. S., Choyke, P., Walther, M., Pack, S., Hurley, K., Andrey, C., Klausner, R., and Linehan, W. M. Improved detection of germline mutations in the VHL tumor suppressor gene. Hum. Mutat., 12: 417-423, 1998.
15. Stebbins, C. E. Kaclin, Jr., W. G., and Paveletich, N. P. Structure of the VHL-elongin C-elongin B complex: implication for VHL tumor suppressor function. Science (Wash. DC), 284: 455-461, 1999.
16. Pause, A., Peterson, B., Schaffar, G., Stearman, R., and Klausner, R. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKPI/cullin/F-box protein. Proc. Natl. Acad. Sci. USA, 96: 9533-9538, 1999.
17. Longergan, K. M., Illiopoulos, O., Ohh, M., Kamura, T., Conaway, R. C., Conaway, J. W., and Kaelin, W. G. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau protein requires binding to complexes containing elonginsB/C and Cul2. Mol. Cell. Biol., 18: 732-741, 1998.
18. Kamura, T., Koepp, D. M., Conrad, M. N., Skowyra, D., Moreland, R. J., Iliopoulos, O., Lane, W. S., Kaelin, W. G. J., Elledge, S. J., Conaway, R. C., Harper, J. W., and Conaway, J. W. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science (Wash. DC), 284: 657-661, 1999.
19. Ohh, M., Takagi, Y., Aso, T., Stebbins, C., Pavletich, N., Zbar, B., Conaway, R., Conaway, J., and Kaelin, W. G. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J. Clin. Investig., 104: 1583-1591, 1999.
20. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., and Ratcliffe, P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (Lond.), 399: 271-275, 1999.
21. Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T-Y., Huang, L. E., Chau, V., and Kaelin, W. G. Ubiquitination of HIF requires direct binding to the von Hippel-Lindau protein [β] domain. Nat. Cell Biol., 2: 423-427, 2000.
22. Kamura, T., Conaway, J. W., and Conaway, R. C. Roles of SCF and VHL ubiquitin ligases in regulation of cell growth. Prog. Mol. Subcell. Biol., 29: 1-15, 2002.
23. Kondo, K., and Kaelin, W. G., Jr. The von Hippel-Lindau tumor suppressor gene. Exp. Cell Res., 264: 117-125, 2001.
24. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev., 12: 149-162, 1998.
25. Ivanov, S. V., Kuzmin, I., Wei, M-H., Pack, S., Geil, L., Johnson, B. E., Stanbridge, E. J., and Lerman, M. I. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA, 95: 12596-12601, 1998.
26. Ebert, B. L., Firth, J. D., and Ratcliffe, P. J. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences. J. Biol. Chem., 270: 29083-29089, 1995.
27. Bunn, H. F., Gu, J., Huang, L. E., Park, J. W., and Zhu, H. Erythropoetin: a model system for studying oxygen-dependent gene regulation. J. Exp. Biol., 201: 1197-1201, 2001.
28. Ang, S. O., Chen, H., Hirota, K., Gordeuk, V. R., Jelinek, J., Guan, Y., Liu, E., Sergueeva, A. I., Miasnikova, G. Y., Mole, D., Maxwell, P. H., Stockton, D. W., Semenza, G. L., and Prchal, J. T. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat. Genet., 32: 614-621, 2002.
29. Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliffe, P. J., and Maxwell, P. H. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell, 1: 459-468, 2002.
30. Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P., and Krek, W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat. Cell Biol., 5: 64-70, 2003.
31. Ohh, M., Yauch, R. L., Lonergan, K. M., Whaley, J. M., Stemmer-Rachamimov, A. O., Loius, D. N., Gavin, B. J., Kley, N., Kaelin, W. G., and Iliopoulos, O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell, 1: 959-968, 1998.
32. Hoffman, M. A., Ohh, M., Yang, H., Klco, J. M., Ivan, M., and Kaelin, W. G., Jr. von Hippel-Lindau protein mutants linked to type2C VHL disease preserve the ability to down-regulate HIF. Hum. Mol. Genet., 10: 1019-1027, 2001.
33. Gnarra, J. R., Ward, J. M., Porter, F. D., Wagner, J. R., Deveo, D. E., Grinberg, A., Emmert-Buck, M. R., Westphal, H., Klausner, R. D., and Linehan, W. B. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. USA, 94: 9102-9107, 1997.
34. Haase, V. H., Glickman, J. N., Socolovsky, M., and Jaenisch, R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. USA, 98: 1583-1588, 2001.
35. Lubensky, I. A., Gnarra, J. R., Bertheau, P., Walther, M. M., Linehan, W. M., and Zhuang, Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am. J. Pathol., 149: 2089-2094, 1996.
36. Tessarollo, L. Manipulating mouse embryonic stem cells. Methods Mol. Biol., 158: 47-63, 2001.
37. Bonin, A., Reid, S. W., and Tessarollo, L. Isolation, microinjection and transfer of mouse blastocysts. Methods Mol. Biol., 158: 121-134, 2001.
38. Gunning, P., Leavitt, J., Muscat, G., Ng, S. Y., and Kedes, L. A human [β]-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl. Acad. Sci. USA, 84: 4831-4835, 1987.
39. Soriano, P. Generalized LacZ expression with the ROSA 26 Cre reporter strain. Nat. Genet., 21: 70-77, 1999.
40. Guo, C., Yang, W., and Lobe, C. A Cre recombinase transgene with mosaic, widespread tamoxifen-inducible action. Genesis, 32: 8-18, 2002.
41. Wang, Y., Krushel, L. A., and Edelman, G. M. Targeted DNA recombination in vivo using an adenovirus carrying the cre recombinase gene. Proc. Natl. Acad. Sci. USA, 93: 3932-3936, 1996.
42. Akagi, K., Sandig, V., Vooigs, M., Van der Valk, M., Giovannini, M., Strauss, M., and Berns, A. Cre-mediated somatic site-specific recombination in mice. Nucleic Acids Res., 25: 1766-1773, 1997.
43. Palko, M. E., Coppola, V., and Tessarollo, L. Evidence for a role of truncated trkC receptor isoforms in mouse development. J. Neurosci., 19: 775-782, 1999.
44. Kessler, P. M., Vasavada, S. P., Rackley, R. R., Stackhouse, T., Duh, F. M., Latif, F., Lerman, M. I., Zbar, B., and Williams, B. R. G. Expression of the von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol. Med., 1: 457-466, 1995.
45. Wenger, R. H., Rolfs, A., Spielmann, P., Zimmermann, D. R., and Gassmann, M. Mouse hypoxia-inducible factor 1-α is encoded by two different mRNA isoforms: expression from a tissue-specific and a housekeeping-type promoter. Blood, 91: 3471-3480, 1998.
46. Marti, H. H., Katschinski, D. M., Wagner, K. F., Schaffer, L., Stier, B., and Wenger, R. H. Isoform-specific expression of hypoxia-inducible factor 1-α during the late stages of mouse spermiogenesis. Mol. Endocrinol., 16: 234-243, 2002.
47. Davidowitz, E. J., Schoenfeld, A. R., and Burk, R. D. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol. Cell. Biol., 21: 865-874, 2001.
48. Murata, H., Tajima, N., Nagashima, Y., Yao, M., Baba, M., Goto, M., Kawamoto, S., Yamamoto, I., Okuda, K., and Kanno, H. von Hippel-Lindau tumor suppressor protein transforms human neuroblastoma cells into functional neuron-like cells. Cancer Res., 62: 7004-7011, 2002.
49. Kanno, H., Saljooque, F., Yamamoto, I., Hattori, S., Yao, M., and Shuin, T. Role of the von Hippel-Lindau tumor suppressor protein during neuronal differentiation. Cancer Res., 60: 2820-2824, 2000.
50. Kneitz, B., Cohen, P. E., Avdievich, E., Zhu, L., Kane, M. F., Hou, H., Jr., Kolodner, R. D., Kucherlapati, R., Pollard, J. W., and Edelmann, W. MutS homolog4 localization to meiotic chromosomes is required for chromosome pairing during meiosis in male and female mice. Genes Dev., 14: 1085-1097, 2000.
51. Her, C., Wu, X., Griswold, M. D., and Zhou, F. Human MutS homologue MSH4 physically interacts with von Hippel-Lindau tumor suppressor-binding protein 1. Cancer Res., 63: 865-872, 2003.
52. Geissler, S., Siegers, K., and Schiebel, E. A novel protein complex promoting formation of functional α- and γ-tubulin. EMBO J., 17: 952-966, 1998.
53. Tsuchiya, H., Iseda, T., and Hino, O. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res., 56: 2881-2885, 1996.
54. Bordeau, A., Faughnan, M. E., McDonald, M-L., Paterson, A. D., Wanless, I. R., and Letarte, M. Potential role of modifier genes influencing transforming growth factor-β1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am. J. Pathol., 158: 2011-2020, 2001.
55. Kobayashi, T., Minowa, O., Kuno, J., Mitani, H., Hino, O., and Noda, T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germline Tsc2 mutation in mice. Cancer Res., 59: 1206-1211, 1999.
56. Kobayashi, T., Minowa, O., Sugitani, Y., Takai, S., Mitani, H., Kobayashi, E., Noda, T., and Hino, O. A germ-line Tsc1 mutation caused tumor development and embryonic lethality that are similar but not identical to those caused by Tsc2 mutation in mice. Proc. Natl. Acad. Sci. USA, 98: 8762-8767, 2001.